Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) shares reached a new 52-week high on Wednesday . The company traded as high as $38.62 and last traded at $37.74, with a volume of 400047 shares changing hands. The stock had previously closed at $38.02.
Analyst Upgrades and Downgrades
Several analysts recently commented on the stock. Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. HC Wainwright raised their price target on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Zacks Research cut Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 17th. Craig Hallum increased their target price on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Finally, B. Riley Financial raised their price objective on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a report on Friday, March 20th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $41.00.
View Our Latest Stock Report on ETON
Eton Pharmaceuticals Stock Performance
Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.05). The business had revenue of $24.27 million during the quarter, compared to the consensus estimate of $22.31 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%. As a group, equities analysts expect that Eton Pharmaceuticals, Inc. will post 0.75 EPS for the current year.
Insider Buying and Selling at Eton Pharmaceuticals
In other Eton Pharmaceuticals news, insider David Krempa sold 42,797 shares of Eton Pharmaceuticals stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83. Following the completion of the sale, the insider directly owned 25,249 shares of the company’s stock, valued at approximately $843,064.11. The trade was a 62.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jennifer Mckie Adams sold 50,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the transaction, the director owned 50,000 shares in the company, valued at $1,624,000. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 150,000 shares of company stock worth $4,853,921. 16.49% of the stock is owned by insiders.
Institutional Trading of Eton Pharmaceuticals
Large investors have recently made changes to their positions in the company. Quarry LP acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth approximately $37,000. Legal & General Group Plc bought a new stake in shares of Eton Pharmaceuticals during the second quarter valued at approximately $41,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter worth approximately $44,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter worth approximately $74,000. Finally, SG Americas Securities LLC bought a new position in shares of Eton Pharmaceuticals in the 4th quarter worth $109,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.
The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.
Read More
- Five stocks we like better than Eton Pharmaceuticals
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
